专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2010522774A Method for treating an angiogenic ocular disease 审中-公开
公开(公告)号：JP2010522774A
公开(公告)日：2010-07-08
申请号：JP2010501409
申请日：2008-03-27
申请人：コンビナトークス、インコーポレイテッドCombinatorx Incorporated , フォベア、ファルマスティカル、ソシエテ、アノニムFovea Pharmaceuticals Sa
发明人：エリザベス、ラトゥール , ジャン‐フィリップ、コンバル , ピエール、ベリシャル
IPC分类号： A61K45/06 , A61K31/573 , A61K38/00 , A61P9/00 , A61P9/10 , A61P27/02 , A61P43/00
CPC分类号： A61K31/573 , A61K31/56 , A61K38/13 , A61K45/06 , A61K2300/00
摘要：本発明は、望ましくない眼血管形成を阻害するための組成物および方法に関する。さらに詳しくは、本発明は、二次療法と組み合わせてＶＥＧＦを阻害する薬剤を用い、眼の血管新生を治療するための組成物および方法に関する。

2. 发明专利

JP2010540671A Formulations for aqueous eye 有权
公开(公告)号：JP2010540671A
公开(公告)日：2010-12-24
申请号：JP2010528310
申请日：2008-10-08
申请人：フォベア、ファルマスティカル、ソシエテ、アノニムFovea Pharmaceuticals Sa
发明人：エリザベス、ラトゥール , ジャン、フィリップ、コンバル , ハルン、タクルリ
IPC分类号： A61K38/00 , A61K9/08 , A61K31/573 , A61K47/12 , A61K47/34 , A61P7/10 , A61P11/00 , A61P11/02 , A61P17/00 , A61P27/02 , A61P27/06 , A61P27/10 , A61P27/12 , A61P27/14 , A61P27/16
CPC分类号： A61K31/573 , A61K9/0048 , A61K38/13 , A61K47/10 , A61K47/26 , A61K2300/00
摘要： Storage-stable, topically ocularly administrable aqueous ophthalmic formulations containing at least one closporine are useful for treating and/or preventing ophthalmic diseases or disorders afflicting humans or animals, notably related to inflammatory conditions, more particularly administrable to the front of the eye and which provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision.

3. 发明专利

JP2009535371A Methods for the treatment of angiogenic diseases 审中-公开
公开(公告)号：JP2009535371A
公开(公告)日：2009-10-01
申请号：JP2009508224
申请日：2007-05-04
申请人：フォベア、ファルマスティカル、ソシエテ、アノニムFovea Pharmaceuticals Sa , フォンダスィオン、オプタルモロジク、アドルフ、ド、ロートシルトFondation Ophthalmologique Adolphe De Rothschild
发明人：ジョゼ、サエル , セバスチャン、ボヌル
IPC分类号： A61K45/06 , A61K38/43 , A61K38/48 , A61K39/395 , A61P9/10 , A61P9/14 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00
CPC分类号： A61K38/49 , A61K39/395 , A61K45/06 , A61K2300/00
摘要：本発明は、眼組織の血管形成を含む望ましくない血管形成を阻害するための組成物および方法に関する。より具体的には、ＶＥＧＦを阻害する薬剤を二次療法と組み合わせて用い、眼組織の血管新生を含む血管新生を治療するための組成物および方法に関する。

4. 发明申请

WO2010092041A1 [1, 2, 4] TRIAZOLO [1, 5 -A] PYRIDINES AS KINASE INHIBITORS 审中-公开
标题翻译： [1，2，4] TRIAZOLO [1,5-A]吡啶作为激酶抑制剂
公开(公告)号：WO2010092041A1
公开(公告)日：2010-08-19
申请号：PCT/EP2010/051556
申请日：2010-02-09
申请人： FOVEA PHARMACEUTICALS SA , LERICHE, Caroline , AUCLAIR, Eric , LE ROUX, Jacques , MIDDLEMISS, David
发明人： LERICHE, Caroline , AUCLAIR, Eric , LE ROUX, Jacques , MIDDLEMISS, David
IPC分类号： C07D471/04 , A61K31/437 , A61P27/02
CPC分类号： C07D471/04
摘要： The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted triazolopyridine compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder. In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.
摘要翻译：本发明涉及某些新化合物，其制备方法和用于治疗或改善激酶介导的病症的方法。更具体地，本发明涉及可用作选择性激酶抑制剂的取代的三唑并吡啶化合物，用于制备这些化合物的方法和用于治疗或改善激酶介导的病症的方法。特别地，所述方法涉及治疗或改善包括心血管疾病，糖尿病，糖尿病相关疾病，炎性疾病，免疫学疾病，癌症和眼睛疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病的激酶介导的疾病，以及类似。

5. 发明申请

WO2010076238A1 SUBSTITUTED QUINAZOLINE COMPOUNDS 审中-公开
标题翻译：取代的喹啉腈化合物
公开(公告)号：WO2010076238A1
公开(公告)日：2010-07-08
申请号：PCT/EP2009/067494
申请日：2009-12-18
申请人： FOVEA PHARMACEUTICALS SA , LERICHE, Caroline , AUCLAIR, Eric , LE ROUX, Jacques , MIDDLEMISS, David, N.
发明人： LERICHE, Caroline , AUCLAIR, Eric , LE ROUX, Jacques , MIDDLEMISS, David, N.
IPC分类号： A61K31/502 , C07D401/14 , C07D403/04 , A61P35/00
CPC分类号： C07D401/14 , C07D403/04
摘要： The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder, In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.
摘要翻译：本发明涉及某些新化合物，其制备方法和用于治疗或改善激酶介导的病症的方法。更具体地，本发明涉及可用作选择性激酶抑制剂的取代喹唑啉化合物，用于制备这些化合物的方法以及用于治疗或改善激酶介导的病症的方法。特别地，该方法涉及治疗或改善激酶介导的病症，包括心血管疾病，糖尿病，糖尿病相关疾病，炎性疾病，免疫学障碍，癌症和眼睛疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病等。

6. 发明申请

WO2009046967A1 AQUEOUS OPHTHALMIC FORMULATIONS 审中-公开
标题翻译：水性眼科配方
公开(公告)号：WO2009046967A1
公开(公告)日：2009-04-16
申请号：PCT/EP2008/008482
申请日：2008-10-08
申请人： FOVEA PHARMACEUTICALS SA , COMBAL, Jean, Philippe , LATOUR, Elisabeth , TAKRURI, Harun
发明人： COMBAL, Jean, Philippe , LATOUR, Elisabeth , TAKRURI, Harun
IPC分类号： A61K47/10 , A61K47/26 , A61K38/13 , A61K31/573
CPC分类号： A61K31/573 , A61K9/0048 , A61K38/13 , A61K47/10 , A61K47/26 , A61K2300/00
摘要： The present invention relates to aqueous ophthalmic formulations containing cyclosporine and methods for treating and/or preventing ophthalmic diseases or disorders of humans or animals. The present ophthalmic formulations and methods are highly suitable for ocular administration, more particularly administration in the front of the eye, and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. More specifically, the present invention relates to ophthalmic formulations and methods for preventing and/or treating ophthalmic diseases or disorders directly and/or indirectly related to inflammatory conditions.
摘要翻译：本发明涉及含有环孢菌素的水性眼用制剂和用于治疗和/或预防人类或动物眼科疾病或病症的方法。目前的眼用制剂和方法非常适合于眼部给药，更特别的是在眼前施用，并且对眼睛提供治疗效果，因为它们有效地稳定，增强和/或改善患者的视力。更具体地，本发明涉及用于预防和/或治疗眼科疾病或病症的眼用制剂和方法，所述眼科疾病或病症与炎性病症直接和/或间接相关。

7. 发明申请

WO2007128526A2 METHODS FOR TREATING NEOVASCULAR DISEASES 审中-公开
标题翻译：治疗新生血管疾病的方法
公开(公告)号：WO2007128526A2
公开(公告)日：2007-11-15
申请号：PCT/EP2007/003967
申请日：2007-05-04
申请人： FOVEA PHARMACEUTICALS SA , FONDATION OPHTALMOLOGIQUE ADOLF DE ROTHSCHILD , BONNEL, Sebastien
发明人： BONNEL, Sebastien
IPC分类号： A61K45/06 , A61K39/395 , A61K38/49 , A61P27/02
CPC分类号： A61K38/49 , A61K39/395 , A61K45/06 , A61K2300/00
摘要： The present Invention relates to compositions and methods for inhibiting unwanted angiogenesis, including that of ocular tissues. More specifically, it relates to compositions and methods for treating neovascularization, including that of ocular tissues, using agents that inhibit VEGF in combination with a second therapy.
摘要翻译：本发明涉及抑制不想要的血管生成的组合物和方法，包括眼组织的组合物和方法。更具体地，本发明涉及使用与第二疗法组合抑制VEGF的药物治疗新血管形成的组合物和方法，包括眼组织的组合物和方法。

8. 发明申请

WO2007128526A3 COMBINATION COMPRISING A VEGF INHIBITOR AND A SERINE PROTEASE FOR TREATING NEOVASCULAR DISEASES 审中-公开
标题翻译：包含VEGF抑制剂和丝氨酸蛋白酶治疗新生血管疾病的组合
公开(公告)号：WO2007128526A3
公开(公告)日：2008-02-28
申请号：PCT/EP2007003967
申请日：2007-05-04
申请人： FOVEA PHARMACEUTICALS SA , FOND OPHTHALMOLOGIQUE ADOLPHE , BONNEL SEBASTIEN
发明人： BONNEL SEBASTIEN
IPC分类号： A61K45/06 , A61K38/49 , A61K39/395 , A61P27/02
CPC分类号： A61K38/49 , A61K39/395 , A61K45/06 , A61K2300/00
摘要： The present Invention relates to compositions and methods for inhibiting unwanted angiogenesis, including that of ocular tissues. More specifically, it relates to compositions and methods for treating neovascularization, including that of ocular tissues, using agents that inhibit VEGF in combination with a second therapy.
摘要翻译：本发明涉及抑制不想要的血管发生的组合物和方法，包括眼组织的组合物和方法。更具体地，本发明涉及使用与第二疗法组合抑制VEGF的药物治疗新血管形成的组合物和方法，包括眼组织的组合物和方法。

9. 发明申请

WO2009083185A3 COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF CELLULAR DEGENERATIVE OPHTHALMIC DISORDERS 审中-公开
标题翻译：预防和治疗细胞性衰老性眼病的组合物和方法
公开(公告)号：WO2009083185A3
公开(公告)日：2010-01-14
申请号：PCT/EP2008010922
申请日：2008-12-19
申请人： FOVEA PHARMACEUTICALS SA , GALY ANNE , BERDUGO NAOMI
发明人： GALY ANNE , BERDUGO NAOMI
IPC分类号： A61K38/17 , A61P27/02
CPC分类号： A61K38/005
摘要： The present application relates to novel therapeutic strategies for cellular degenerative ophthalmic diseases, and more specifically diseases associated with photoreceptors degeneration such as age-related macular degeneration, retinitis pigmentosa, macular and retinal edema and uveitis. The invention relates to a novel use of Unc51-Like Kinase modulator, and more specifically of Unc51-Like Kinase inhibitors. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of cellular degenerative ophthalmic diseases.
摘要翻译：本申请涉及用于细胞性退行性眼科疾病的新型治疗策略，更具体地涉及与感光器变性相关的疾病，例如年龄相关性黄斑变性，色素性视网膜炎，黄斑和视网膜水肿和葡萄膜炎。本发明涉及Unc51样激酶调节剂的新用途，更具体地涉及Unc51样激酶抑制剂。本发明的化合物可用于制备用于预防和治疗细胞性退行性眼科疾病的药物组合物。

10. 发明申请

WO2009083185A2 COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF CELLULAR DEGENERATIVE OPHTHALMIC DISORDERS 审中-公开
标题翻译：预防和治疗细胞性衰老性眼病的组合物和方法
公开(公告)号：WO2009083185A2
公开(公告)日：2009-07-09
申请号：PCT/EP2008/010922
申请日：2008-12-19
申请人： FOVEA PHARMACEUTICALS SA , GALY, Anne , BERDUGO, Naomi
发明人： GALY, Anne , BERDUGO, Naomi
CPC分类号： A61K38/005
摘要： The present application relates to novel therapeutic strategies for cellular degenerative diseases, and more specifically neurodegenerative diseases. Said strategies are based on modulating one or more metabolic pathways identified by the inventors, which are correlated with the onset, development and progression of toxicity and apoptosis in cells, especially nerve cells, and are particularly pertinent in neurodegenerative diseases. The invention relates to a novel use of Unc51-Like Kinase modulator, and more specifically of Unc51-Like Kinase inhibitors. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of cellular degenerative diseases, and more specifically neurodegenerative disorders.
摘要翻译：本申请涉及细胞退行性疾病的新型治疗策略，更具体地涉及神经变性疾病。所述策略基于调节发明人鉴定的一种或多种代谢途径，其与细胞，特别是神经细胞中的毒性和凋亡的发生，发展和进展相关，并且与神经变性疾病特别相关。本发明涉及Unc51样激酶调节剂的新用途，更具体地涉及Unc51样激酶抑制剂。本发明的化合物可用于制备用于预防和治疗细胞变性疾病的药物组合物，更具体地说是神经变性疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式